MedTrace Logo

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

NCT01892241 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2013-10-01

No results posted yet for this study

Summary

Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.

Conditions

  • Antiviral Treatment of Chronic Hepatitis B

Interventions

DRUG

Pegasys(Roche)

180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.

DRUG

Entecavir

continual entecavir therapy(0.5 mg orally once daily)

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Gao Zhiliang, doctor · The Third Affliated Hospital of Sun Yat-sen University

  • Zhao Zhixin, doctor · The Third Affliated Hospital of Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-11-30
Completion
2013-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01892241 on ClinicalTrials.gov